NCT02591095已完成2 期
A Study of ABT-263 as Single Agent in Women With Platinum Resistant/Refractory Recurrent Ovarian Cancer
Centre Francois Baclesse16 个研究点 分布在 1 个国家目标入组 47 人开始时间: 2016年1月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 47
- 试验地点
- 16
- 主要终点
- The primary endpoint is the progression-free survival (PFS) in the whole cohort of patients with a recurrent platinum-resistant ovarian cancer.
研究概览
简要总结
ABT-263 as single agent in women with platinum resistant/refractory recurrent ovarian cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •- Woman older than 18 years
- •Subjects with Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
- •Histologically and/or cytologically documented high grade serous epithelial cancer of ovarian, fallopian tube or peritoneum
- •Platinum resistant ovarian cancer defined as relapsing within 6 months after a platinum based chemotherapy OR platinum refractory ovarian cancer defined as progressing during a platinum based chemotherapy (excepted refractory patients in first line)
- •Subjects having received at least 2 prior lines of treatments including platinum regimen
- •Subjects who are willing and able to comply with the protocol and study procedures including willingness to undergo tumor biopsy before therapy at screening
- •There is no limitation to prior number of therapies
- •Patients must have documented disease progression
- •Subjects who have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
- •Adequate bone marrow, renal and hepatic function per local laboratory reference range as follows:• Absolute Neutrophil Count ≥ 1500/ mm3
- •Platelets ≥ 150,000 / mm3
- •Hemoglobin ≥ 9.0 g/dL
- •Renal function: Serum creatinine ≤1.2mg/dL or calculated creatinine clearance ≥ 60mL/min
- •AST/ALT ≤ 3.0× the upper limit of normal (ULN); [Subjects with liver metastasis may have AST, ALP, and ALT less then or equal to 5.0 X ULN]
- •Bilirubin ≤ 1.25×ULN
- •Coagulation: aPTT and PT not to exceed 1.2 × ULN
- •LVEF > 50% by echocardiograms or MUGA
- •Patients must give written informed consent
排除标准
- •Patient's refusal or impossibility to perform biopsy on relapsing disease
- •Bowel occlusive syndrome or other gastro-intestinal disorder that does not allow oral medication such as malabsorption
- •Patients with platinum refractory disease in first line
- •Received radio-immunotherapy within 6 months of 1st dose of study drug
- •Received steroid therapy for anti-neoplastic intent within 7 days of the 1st dose of study drug (Inhaled steroids for asthma, topical steroids, replacement/stress corticosteroids, or corticosteroids taken as premedication are allowed)
- •Consumption of grapefruit or grapefruit products within 3 days prior to the first dose of study drug
- •Patient receiving treatments strong CYP3A4 inhibitors or inducers (Appendix A)
- •Positive for HIV and VHC
- •Predisposing condition/currently exhibiting signs of bleeding
- •Currently receiving anticoagulation therapy, exception of low-dose anticoagulation medications for prophylaxis
- •Received aspirin within 7 days of start dose of study drug
- •Active peptic ulcer disease / other potentially hemorrhagic esophagitis/gastritis
- •Active immune thrombocytopenic purpura, autoimmune hemolytic anemia or history of being refractory to platelet transfusions (within 1 year of 1st dose of study drug)
- •Uncontrolled cardiac, renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, or hepatic disease, active systemic fungal infection; diagnosis of fever and neutropenia within 1 week of study drug administration
- •A evidence of current/active malignancies other than ovarian cancer
- •Pregnant or lactating women
研究组 & 干预措施
ABT-263
Experimental
oral Navitoclax (ABT-263) daily
干预措施: ABT-263 (Drug)
结局指标
主要结局
The primary endpoint is the progression-free survival (PFS) in the whole cohort of patients with a recurrent platinum-resistant ovarian cancer.
时间窗: the time to progression (or death from any cause) from date of randomization until date of first documented progression or date of death from any cause,whichever came first, assessed up to 12 months. Evaluation at interim and final analyses.
次要结局
- Bim expression level(biopsy sample before initiation of treatment by ABT-263 and assessment within 6 months after end of inclusions)
- Response rate(evaluated every 6 weeks during treatment to progression or death for any cause.(during average 12 months)])
- Overall survival (OS)(From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months.)
- Incidence of Treatment-Emergent Adverse Events according to the NCI CTC AE version 4.0(From date of treatment start until end of study participation (during average 12 months)])
- Peak Plasma Concentration of ABT-263(8-hour post-dose PK on D1 of C1 & 2. Dosage will be done within 12 months after end of inclusions)
- Residual concentration of ABT-263(Pre-dose 0 and cycles 3, 4, 6 . Dosage will be done within 12 months after end of inclusions)
研究者
研究点 (16)
Loading locations...
相似试验
招募中
2 期
A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.Platinum-resistant Recurrent Ovarian CancerNCT06434610Shanghai Jiaolian Drug Research and Development Co., Ltd90
已完成
2 期
Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynaecological neoplasmsACTRN12610000796088niversity of Sydney333
终止
2 期
Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian CancerOvarian CancerNCT03587129First Affiliated Hospital of Harbin Medical University1
已完成
3 期
Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian CancerRecurrent Platinum-sensitive Ovarian CancerNCT01837251AGO Research GmbH682
招募中
不适用
Platino-resistance in Ovarian CancerEpithelial Ovarian CancerNCT03954171Institut Claudius Regaud600